Bayer's Two-Front Offensive: A Chinese Regulatory Filing and a Leaner Machine
Published on 08/01/2026 at 05:11 | Redaktion boerse-global.de
The turnaround story at Bayer has acquired a distinctly operational edge. On one front, the Leverkusen-based conglomerate is pushing to expand the medical reach of its kidney drug Kerendia, filing a fresh application with China's National Medical Products Administration. On the other, the cost-cutting revolution engineered by CEO Bill Anderson is beginning to show up in the share price — and in the confidence of investors who once wouldn't touch the stock.
A New Indication for Finerenon
The submission to the Center for Drug Evaluation, a division of the NMPA, seeks approval for finerenon — marketed as Kerendia and Firialta — in adults with non-diabetic chronic kidney disease. That would mark a substantial broadening of the drug's current label, which already covers kidney disease tied to type-2 diabetes and specific forms of heart failure across more than 100 countries.
The application rests on data from the FIND-CKD Phase 3 trial, presented at the ERA congress in 2026 and subsequently published in the New England Journal of Medicine. The results showed finerenon significantly slowed the progression of kidney disease compared with placebo when added to standard therapy, while also reducing cardiovascular and renal events.
The potential patient pool is enormous. Roughly 850 million people worldwide live with chronic kidney disease, and in more than half of those cases, diabetes is not the underlying cause. Bayer points out that in advanced stages of the disease, the risk of kidney failure and cardiovascular events runs about 2.6 times higher than in the general population.
China is central to Bayer's pharma ambitions, and Kerendia is regarded as one of the most important assets in the company's pipeline — a candidate to offset revenue losses from older drugs facing patent expiries. Each additional indication and market brings that goal closer.
The Anderson Effect
The stock's recent trajectory tells a story of its own. Bayer shares closed Friday at €48.49, up 5.48 percent over the week — a meaningful rebound after months of weakness. Year-to-date, the shares have gained 31.02 percent. A separate reading from the end of July put the price at €48.14, with a 12-month gain of 76.95 percent and a 30.07 percent advance since the start of the year.
That rally is not merely a technical bounce, according to market observers. It reflects a deeper transformation under Anderson's "Dynamic Shared Ownership" model. The CEO has dismantled a management structure that once had up to twelve layers of hierarchy, replacing it with roughly 2,000 self-organizing teams. The target: €2 billion in annual savings by the end of 2026.
Legal relief has added fuel. Recent rulings, including from the US Supreme Court, have given Bayer a clearer path to capping the glyphosate litigation risk that long hung over the company like a dark cloud. What was once an unpredictable wave of lawsuits now has a more calculable shape.
The pharma pipeline has also brightened. Asundexian, the company's experimental anticoagulant, delivered positive Phase 3 data and is now under priority review by the FDA, with the EMA also examining it. If approved, the drug could more than compensate for patent losses on blockbusters like Xarelto.
Just as Bayer is managing operational risks across its global business, UK employers face their own compliance obligations when it comes to workplace safety. A free Risk Assessment Toolkit with 41 ready-to-use templates and checklists can help you document hazards and protect your workforce. Download the free Risk Assessment Toolkit
Chart Position and the August Test
Technically, the stock remains in solid shape. It trades 22.80 percent above its 200-day moving average, and the relative strength index sits at 57.5 — a level that suggests the rally has room to run without being overbought, even after a 4.72 percent surge in seven days. The market capitalization stands at €46.85 billion, still shy of the 52-week high of €53.86.
Chart analysts note that the shares have broken through key resistance levels and exited a consolidation phase. However, trading volume has only ticked up modestly — a sustainable uptrend typically requires stronger institutional participation. Without that confirmation, the risk of a false signal remains. Summer's thinner liquidity could amplify swings on company news.
The Kerendia filing provides operational tailwind for the ongoing recovery. The real test, though, comes on Tuesday, August 4, 2026, when Bayer releases its half-year results. That will be the first genuine evidence of whether Anderson's efficiency program is translating into the numbers — or whether the rally has gotten ahead of the fundamentals.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
